Multiple Myeloma Measurable Residual Disease (MRD), Flow Cytometry, Bone Marrow
Use
Detecting low-level measurable residual disease (MRD) in patients with multiple myeloma post-therapy is a significant prognostic marker. The presence of MRD indicates remaining cancerous plasma cells, which can predict patient outcomes. This test employs high-sensitivity flow cytometry, following EuroFlow guidelines, to assess MRD levels with a sensitivity of 10(-5) or better. It is essential for monitoring remission and guiding treatment decisions post-chemotherapy or autologous stem cell transplantation in multiple myeloma patients.
Special Instructions
Not provided.
Limitations
Current gating strategies may not detect abnormal plasma cells if they do not phenotypically differ from normal cells. Therapeutic antibodies may also interfere with antigen expression. Specimen processing affects plasma cell percentage, and sensitivity may diminish with low event collections.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 93022-2
- 93021-4
- 93020-6
- 38257-2
- 93019-8
- 93018-0
- 93017-2
- 74226-2
- 101131-1
- 101130-3
- 101129-5
- 87706-8
- 101128-7
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
2 mL
Container
Yellow top (ACD solution A or B) preferred, Lavender top (EDTA) acceptable
Collection Instructions
Specimens should arrive within 2 days of collection. Collect and package specimens as close to shipping time as possible.
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |